Literature DB >> 27058661

Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.

Andy J Minn1, E John Wherry2.   

Abstract

Improving efficacy of immune checkpoint blockade for cancer can be facilitated by combining these agents with each other and/or with other conventional or targeted therapies. Interferon and innate immune signaling pathways in immune and tumor cells have emerged as intriguing determinants of response and resistance, often in complex and seemingly paradoxical ways.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27058661     DOI： 10.1016/j.cell.2016.03.031

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  95 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

2.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

3.  Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer.

Authors:  Merit L Goodman; Gloria M Trinca; Katherine R Walter; Evangelia K Papachristou; Clive S D'Santos; Tianbao Li; Qi Liu; Zhao Lai; Prabhakar Chalise; Rashna Madan; Fang Fan; Mary A Markiewicz; Victor X Jin; Jason S Carroll; Christy R Hagan
Journal:  J Immunol       Date:  2019-04-01       Impact factor: 5.422

4.  Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.

Authors:  Chen Zhu; Cunyi Zou; Gefei Guan; Qing Guo; Zihao Yan; Tianqi Liu; Shuai Shen; Xiaoyan Xu; Chen Chen; Zhiguo Lin; Wen Cheng; Anhua Wu
Journal:  Oncoimmunology       Date:  2019-06-12       Impact factor: 8.110

5.  Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.

Authors:  Boning Liu; Huaizu Guo; Jin Xu; Ting Qin; Qingcheng Guo; Nana Gu; Dapeng Zhang; Weizhu Qian; Jianxin Dai; Sheng Hou; Hao Wang; Yajun Guo
Journal:  MAbs       Date:  2017-12-20       Impact factor: 5.857

Review 6.  IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy.

Authors:  Lionel B Ivashkiv
Journal:  Nat Rev Immunol       Date:  2018-09       Impact factor: 53.106

Review 7.  Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints.

Authors:  Diana Saleiro; Leonidas C Platanias
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

8.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

9.  Local delivery of checkpoints antibodies.

Authors:  Chao Wang; Yanqi Ye; Zhen Gu
Journal:  Hum Vaccin Immunother       Date:  2016-09-26       Impact factor: 3.452

Review 10.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.